Know Cancer

or
forgot password

Minimal Stimulation or Clomiphene Citrate as First Line Therapy in Women With Polycystic Ovary Syndrome


N/A
20 Years
39 Years
Not Enrolling
Female
Polycystic Ovary Syndrome

Thank you

Trial Information

Minimal Stimulation or Clomiphene Citrate as First Line Therapy in Women With Polycystic Ovary Syndrome


All patients received 100 mg CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt) for 5
days starting from day 3 of spontaneous or induced menstruation. In group A (minimal
stimulation), 2 vials of highly purified uFSH , 150 IU (Fostimon; IBSA, Lugano, Switzerland,
75 IU/vial) were given IM on cycle day 9. A total of 3 cycles was offered to each group.


Inclusion Criteria:



- PCOS

- No other infertility factors

- No previous use of ovarian stimulation drugs

Exclusion Criteria:

- Congenital adrenal hyperplasia

- Cushing syndrome

- Androgen secreting tumors

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Outcome Measure:

clinical pregnancy rate per cycle

Safety Issue:

No

Principal Investigator

Hatem Abu Hashim, MD MRCOG

Investigator Role:

Principal Investigator

Investigator Affiliation:

Mansoura University Hospitals

Authority:

Egypt: Institutional Review Board

Study ID:

MU-290s

NCT ID:

NCT01157312

Start Date:

August 2008

Completion Date:

April 2010

Related Keywords:

  • Polycystic Ovary Syndrome
  • Polycystic ovary syndrome
  • clomiphene citrate
  • minimal stimulation
  • infertility treatment
  • Polycystic Ovary Syndrome

Name

Location